News and Press Releases
Press releases
Theralase’s Lead Anti-Cancer Drug Has Significantly Less Skin Toxicity than FDA Approved Drug
Press ReleaseToronto, Ontario – February 13, 2015, Theralase Technologies Inc. (“Theralase”) (TLT:TSXV) (TLTFF: OTC Pink®), a developer of advanced Photo Dynamic Therapy (“PDT”), for serious and life-threatening diseases, announced toda...
Theralase Ranked in 2015 Toronto Stock Exchange Venture 50®
Press ReleaseToronto, Ontario – February 11, 2015, Theralase Technologies Inc. (“Theralase”) (TLT:TSXV) (TLTFF: OTC Pink®) announced today that it has been ranked in the Toronto Stock Exchange Venture (“TSXV”) 50®. Every year, the TSX Ven...
Theralase Files Health Canada Approval for Next Generation Therapeutic Laser
Press ReleaseToronto, Ontario – February 9, 2015, Theralase Technologies Inc. (“Theralase”) (TLT:TSXV) (TLTFF: OTC Pink®) announced today that it has successfully completed the design of the next generation therapeutic laser, the TLC-2000, and...
Theralase Anti-Cancer Technology Research Accepted for Peer Reviewed Publication
Press ReleaseToronto, Ontario, February 3, 2015 /Theralase Technologies Inc. (“Theralase”) (TLT:TSXV) (TLTFF: OTC Pink(R)), a developer of advanced Photo Dynamic Therapy (“PDT“), for serious and life-threatening diseases, announced today that resea...
Theralase’s Latest Research on Anti-Cancer Technology Accepted for Presentation at International Conference
Press ReleaseToronto, Ontario, January 29, 2015 / Theralase Technologies Inc. (“Theralase”) (TLT:TSXV) (TLTFF: OTC Pink(R)) announced today that its latest research on its lead Photo Dynamic Compound (“PDC“) TLD-1433 binding to transferrin has been ...
Theralase Files US Patent Application for Increased Targeting of Photo Dynamic Therapy
Press ReleaseToronto, Ontario – January 20, 2015, Theralase Technologies Inc. (“Theralase”)(TLT:TSXV) (TLTFF: OTC Pink®) announced today that it has filed a provisional US patent application for “Transferrin Enhanced Photo Dynamic Therapy (...
Theralase Identifies Lead Photo Dynamic Compound for Human Clinical Trials
Press ReleaseToronto, Ontario – January 15, 2015, Theralase Technologies Inc. (“Theralase”) (TLT:TSXV) (TLTFF: OTC Pink®) announced today that it has identified its lead Photo Dynamic Compound (“PDC”) that it plans to enter into a Health C...
Theralase to Present at Alpha North Investor Conference
Press ReleaseToronto, Ontario – January 13, 2015, Theralase Technologies Inc. (“Theralase”) (TLT:TSXV) (TLTFF: OTC Pink®) announced today that Roger Dumoulin-White, President and CEO of Theralase will present at the 2nd Annual AlphaNorth Capit...
Theralase Summarizes its 2014 Scientific Achievements and 2015 Strategic Objectives
Press ReleaseToronto, Ontario – January 9, 2015, Theralase Technologies Inc. (“Theralase”) (TLT:TSXV) (TLTFF: OTC Pink®) announced today a summary of its 2014 scientific achievements published in peer reviewed, high impact scientific journals ...
Theralase Reports Results of PDC Therapy of Bladder Cancer in Orthotopic Rat Model
Press ReleaseToronto, Ontario – December 23, 2014, Theralase Technologies Inc. (“Theralase”)(TLT:TSXV) (TLTFF: OTC Pink®) announced today that it has obtained preliminary results from the use of Photo Dynamic Therapy (“PDT”) to destroy bla...
in the news
July 6, 2023
Vrian Crombie Radio Interview with Roger DuMoulin-White - President and Chief Executive Officer
may 18, 2023
Promising Developments in the Theralase® Project of Intravesical Photodynamic Therapy for BCG Unresponsive Bladder Cancer - Girish Kulkarni
Let's Stay in Touch
Sign up to our newsletter to stay informed on news and updates from Theralase Technologies Inc.
